Why We’re Bullish on Resmed – A Deeper Dive into GLP-1 Treatments
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.